Amendment #2 to Project Rider #1, effective as of November 13, 2019, pursuant to the Collaboration Agreement by and between the Registrant and National Marrow Donor Program d/b/a Be The Match BioTherapies, dated as of November 10, 2017
PROJECT RIDER #1
This Amendment #2 to Project Rider #1 (Amendment #2) is entered into effective as of the date of the final signature executing this Amendment #2 (Amendment #2 Effective Date) by and between Magenta Therapeutics, Inc. (Magenta) and National Marrow Donor Program d/b/a Be The Match Biotherapies (BTMB) (each a Party and collectively the Parties).
WHEREAS, the Parties executed a Collaboration Agreement, effective November 10, 2017 and a Project Rider, effective December 6, 2017 (as amended by that certain Amendment #1, effective December 6, 2018, Project Rider #1); and
WHEREAS, the Parties agree to revise the Payment Schedule of the Project Rider #1.
NOW, THEREFORE, for the valuable consideration contained herein, and intending to be legally bound, Magenta and BTMB agree to the following amendment to be effective as of the Amendment #2 Effective Date as follows:
Amendment to Project Rider #1
Delete the Payment Schedule in Section D. Compensation of BTMB of Project Rider #1 in its entirety and replace it with the following to read as follows:
|For Services provided by BTMB during Calendar Year 2020 (January 1, 2020 through December 31, 2020), Magenta will pay BTMB a fixed price quarterly payment of $25,000.|| |
BTMB will invoice $25,000 every January 15th for consulting services occurring during the period commencing January 1st and ending March 31st.
BTMB will invoice $25,000 every April 15th for consulting services commencing April 1st and ending June 30th.
BTMB will invoice $25,000 every July 15th for consulting services commencing July 1st and ending September 30th.
BTMB will invoice $25,000 every October 15th for consulting services commencing October 1st and ending December 31st.
[Remainder of page intentionally left blank.]
This Amendment #2 is executed by individuals who are duly authorized to legally bind their respective parties as of the Amendment #2 Effective Date:
|MAGENTA THERAPEUTICS, INC.||NATIONAL MARROW DONOR PROGRAM d/b/a BE THE MATCH BIOTHERAPIES|
|By:||/s/ Christina Isacson||By:||/s/ Mary Frey|
|Authorized signature||Authorized signature|
|Christina Isacson||Mary Frey|
|(Typed/Printed Name)||(Typed/Printed Name)|
|Title:||Chief Business Officer||Title:||Contracts & Procurement Department|
|Date:||November 13, 2019||Date:||11/12/19|